[{"id":"ca7e4b34-6f76-4ea3-8c6b-e39973324752","acronym":"NRG-LU003","url":"https://clinicaltrials.gov/study/NCT03737994","created_at":"2023-11-21T21:15:46.432Z","updated_at":"2025-02-25T12:37:11.248Z","phase":"Phase 2","brief_title":"Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03737994 - NRG-LU003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" ALK positive • MET amplification • ALK rearrangement","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • MET amplification • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Xalkori (crizotinib) • carboplatin • Alecensa (alectinib) • Lorbrena (lorlatinib) • Zykadia (ceritinib) • pemetrexed • Alunbrig (brigatinib) • Ensacove (ensartinib) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 07/21/2021","primary_completion_date":" 07/21/2021","study_txt":" Completion: 12/02/2025","study_completion_date":" 12/02/2025","last_update_posted":"2025-02-24"},{"id":"d4921ecb-dbf8-4a8b-a82b-331ac066876f","acronym":"ACHIEVE Study","url":"https://clinicaltrials.gov/study/NCT06096844","created_at":"2023-10-24T15:13:40.333Z","updated_at":"2025-02-25T12:38:45.622Z","phase":"Phase 3","brief_title":"Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial","source_id_and_acronym":"NCT06096844 - ACHIEVE Study","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" ALK translocation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • EGFR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 304","initiation":"Initiation: 07/19/2024","start_date":" 07/19/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-02-24"},{"id":"e3b4bad8-8656-47cc-998e-a5d2146657b6","acronym":"ALCHEMIST Screening","url":"https://clinicaltrials.gov/study/NCT02194738","created_at":"2021-01-18T10:15:39.910Z","updated_at":"2025-02-25T12:26:10.714Z","phase":"","brief_title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","source_id_and_acronym":"NCT02194738 - ALCHEMIST Screening","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • PD-L1 • ALK • PIK3CA • PTEN • PD-1 • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Lynparza (olaparib) • cisplatin • Xalkori (crizotinib) • erlotinib • carboplatin • gemcitabine • paclitaxel • docetaxel • Mektovi (binimetinib) • pemetrexed • sapanisertib (CB-228) • Zaltrap (ziv-aflibercept IV) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed) • liposomal gemcitabine (FF-10832)"],"overall_status":"Recruiting","enrollment":" Enrollment 8300","initiation":"Initiation: 09/26/2014","start_date":" 09/26/2014","primary_txt":" Primary completion: 09/28/2026","primary_completion_date":" 09/28/2026","study_txt":" Completion: 09/28/2026","study_completion_date":" 09/28/2026","last_update_posted":"2025-02-24"},{"id":"9272430e-eab6-4fc0-8844-69d711337ecc","acronym":"ENDURE","url":"https://clinicaltrials.gov/study/NCT04892953","created_at":"2021-05-19T15:52:50.047Z","updated_at":"2025-02-25T13:40:30.743Z","phase":"Phase 2","brief_title":"Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy","source_id_and_acronym":"NCT04892953 - ENDURE","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" EGFR • ALK • MET • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement","tags":["EGFR • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 07/07/2021","start_date":" 07/07/2021","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-21"},{"id":"be73eee7-8633-483e-a581-812fd81e01b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04929041","created_at":"2021-06-18T23:52:29.992Z","updated_at":"2025-02-25T14:02:22.824Z","phase":"Phase 2/3","brief_title":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative","source_id_and_acronym":"NCT04929041","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • ALK mutation","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • albumin-bound paclitaxel • pemetrexed • ABP 206 (nivolumab biosimilar) • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 427","initiation":"Initiation: 10/07/2022","start_date":" 10/07/2022","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-19"},{"id":"2b60e541-1e3c-4090-9044-9dd28f2e4baf","acronym":"A092001","url":"https://clinicaltrials.gov/study/NCT05001880","created_at":"2023-11-29T23:15:50.240Z","updated_at":"2025-02-25T14:16:16.072Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","source_id_and_acronym":"NCT05001880 - A092001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 08/20/2025","primary_completion_date":" 08/20/2025","study_txt":" Completion: 08/20/2025","study_completion_date":" 08/20/2025","last_update_posted":"2025-02-17"},{"id":"57381c24-31ec-4c63-b601-61888dd1102a","acronym":"EA5163","url":"https://clinicaltrials.gov/study/NCT03793179","created_at":"2021-01-18T18:45:20.609Z","updated_at":"2025-02-25T16:37:19.034Z","phase":"Phase 3","brief_title":"Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT03793179 - EA5163","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation","tags":["EGFR • PD-L1 • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • pemetrexed • Pembroria (pembrolizumab biosimilar) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 04/05/2019","start_date":" 04/05/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-06"},{"id":"32db2e33-a236-469e-bb51-b652b3d549e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05136846","created_at":"2021-11-29T14:53:44.432Z","updated_at":"2025-02-25T17:01:33.441Z","phase":"Phase 1","brief_title":"Papaverine in Combination with Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05136846","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Pemfexy (pemetrexed) • papaverine"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 12/06/2021","start_date":" 12/06/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-03"},{"id":"2556a800-12ac-4ffc-b124-64c3995bab28","acronym":"AVANZAR","url":"https://clinicaltrials.gov/study/NCT05687266","created_at":"2023-01-18T15:59:54.978Z","updated_at":"2025-02-25T17:31:49.301Z","phase":"Phase 3","brief_title":"Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT05687266 - AVANZAR","lead_sponsor":"AstraZeneca","biomarkers":" EGFR • BRAF • ALK • ROS1 • TACSTD2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1350","initiation":"Initiation: 12/29/2022","start_date":" 12/29/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-01-30"},{"id":"b0b8fd2c-45d2-439d-baa9-7ef0bc159fed","acronym":"TROPION-Lung07","url":"https://clinicaltrials.gov/study/NCT05555732","created_at":"2022-09-27T14:04:32.746Z","updated_at":"2025-02-25T15:00:38.318Z","phase":"Phase 3","brief_title":"Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)","source_id_and_acronym":"NCT05555732 - TROPION-Lung07","lead_sponsor":"Daiichi Sankyo","biomarkers":" EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • BRAF • ALK • RET • ROS1 • TACSTD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Datroway (datopotamab deruxtecan-dlnk) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 1170","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-11-12"},{"id":"cbce4e03-be2e-4cae-8d0d-89ff40fa5446","acronym":"SiCARIO","url":"https://clinicaltrials.gov/study/NCT05501665","created_at":"2022-08-15T12:10:46.917Z","updated_at":"2025-02-25T16:26:59.959Z","phase":"Phase 1/2","brief_title":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","source_id_and_acronym":"NCT05501665 - SiCARIO","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" PD-L1 • PD-1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-10-17"},{"id":"58c1e0c0-b674-448a-ae94-6a539accdd99","acronym":"","url":"https://clinicaltrials.gov/study/NCT05198830","created_at":"2022-01-20T15:53:52.796Z","updated_at":"2024-07-02T16:34:26.376Z","phase":"Phase 2","brief_title":"Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05198830","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/15/2022","start_date":" 12/15/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-13"},{"id":"242a00a6-2e7d-4b18-8a4a-57905c77b105","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05364645","created_at":"2022-05-06T18:55:15.353Z","updated_at":"2024-07-02T16:34:27.438Z","phase":"Phase 2","brief_title":"Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05364645 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • KRAS • BRAF • ALK • MET • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive","tags":["EGFR • KRAS • BRAF • ALK • MET • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • EGFR T790M • RET fusion • MET exon 14 mutation • ALK fusion • ROS1 fusion • MET mutation • RET positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Retevmo (selpercatinib) • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/25/2022","start_date":" 07/25/2022","primary_txt":" Primary completion: 06/27/2023","primary_completion_date":" 06/27/2023","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2024-06-11"},{"id":"d61ddbc3-bb32-4dda-8c4c-406b6f74dc87","acronym":"HARMONIC","url":"https://clinicaltrials.gov/study/NCT05456256","created_at":"2022-07-13T12:56:31.097Z","updated_at":"2024-07-02T16:35:03.235Z","phase":"Phase 2","brief_title":"A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma","source_id_and_acronym":"NCT05456256 - HARMONIC","lead_sponsor":"Lantern Pharma Inc.","biomarkers":" EGFR • ALK • NTRK","pipe":" | ","alterations":" MET exon 14 mutation","tags":["EGFR • ALK • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • pemetrexed • Pemfexy (pemetrexed) • Tavocept (dimesna)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-05-16"},{"id":"7bef29a7-07ed-4332-9706-9ee664c0f131","acronym":"Lung-MAP Non-Match Sub-Study","url":"https://clinicaltrials.gov/study/NCT05096663","created_at":"2021-10-27T14:53:21.327Z","updated_at":"2024-07-02T16:35:05.962Z","phase":"Phase 2/3","brief_title":"Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05096663 - Lung-MAP Non-Match Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1 • NTRK","pipe":" | ","alterations":" BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion","tags":["EGFR • BRAF • ALK • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • ALK fusion • ROS1 fusion • MET mutation • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • Anktiva (nogapendekin alfa inbakicept-pmln) • Hemady (dexamethasone tablets) • Pemfexy (pemetrexed)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 03/15/2022","start_date":" 03/15/2022","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2024-05-03"},{"id":"c4a4883e-de84-42f0-8b66-0e5ccb6e66a9","acronym":"NRG-LU008","url":"https://clinicaltrials.gov/study/NCT05624996","created_at":"2022-11-22T15:59:02.499Z","updated_at":"2024-07-02T16:35:20.409Z","phase":"Phase 3","brief_title":"Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05624996 - NRG-LU008","lead_sponsor":"NRG Oncology","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • etoposide IV • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 474","initiation":"Initiation: 05/10/2023","start_date":" 05/10/2023","primary_txt":" Primary completion: 10/15/2031","primary_completion_date":" 10/15/2031","study_txt":" Completion: 10/15/2036","study_completion_date":" 10/15/2036","last_update_posted":"2024-02-07"},{"id":"23e0ae17-59f0-4190-ae9d-2a3bb406aa11","acronym":"G360-IIT","url":"https://clinicaltrials.gov/study/NCT05715229","created_at":"2023-02-06T15:03:00.616Z","updated_at":"2024-07-02T16:35:23.375Z","phase":"Phase 2","brief_title":"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","source_id_and_acronym":"NCT05715229 - G360-IIT","lead_sponsor":"Hackensack Meridian Health","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 108","initiation":"Initiation: 09/29/2023","start_date":" 09/29/2023","primary_txt":" Primary completion: 04/28/2026","primary_completion_date":" 04/28/2026","study_txt":" Completion: 04/28/2026","study_completion_date":" 04/28/2026","last_update_posted":"2024-01-15"},{"id":"7c4ff31f-11ff-49ce-b363-35381d333f2b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05746481","created_at":"2023-02-27T15:01:18.422Z","updated_at":"2024-07-02T16:35:40.338Z","phase":"Phase 2","brief_title":"Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases","source_id_and_acronym":"NCT05746481","lead_sponsor":"Liza Villaruz, MD","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • pemetrexed • tiragolumab (RG6058) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/08/2023","start_date":" 08/08/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/30/2027","study_completion_date":" 04/30/2027","last_update_posted":"2023-08-10"},{"id":"a432a555-c2f8-43ba-befa-5a91db04db5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535325","created_at":"2021-01-18T12:15:42.112Z","updated_at":"2025-02-25T16:30:42.064Z","phase":"Phase 1","brief_title":"Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer","source_id_and_acronym":"NCT02535325","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ERCC1 • NKX2-1","pipe":"","alterations":" ","tags":["ERCC1 • NKX2-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • pemetrexed • Pemfexy (pemetrexed) • methoxyamine (TRC102)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 02/27/2020","primary_completion_date":" 02/27/2020","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2022-06-30"}]